Meeting
2022 ASCO Annual Meeting
Digital monitoring and assessments in patients with glioblastoma.
Authors
Yasaman Damestani
Karyopharm Therapeutics Inc., Newton, MA
Yasaman Damestani , Ruiyang Shi , Kai Li , Patrice Melikian , Shelley Haybeck , Gregory Mundy , Gursharan Gill , Shijie Tang , Eric Sbar , Tracey Duncan , Sharon Tamir , Eran Shacham , Jatin J. Shah , Sharon Shacham , Patrick Y. Wen , Erin Dunbar , Priya Kumthekar , Howard Colman , Robert Aiken , Nicholas A. Butowski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04421378
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2045)
DOI
10.1200/JCO.2022.40.16_suppl.2045
Abstract #
2045
Poster Bd #
383
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Digital measurement of functional status of patients with glioblastoma.
First Author: Yasaman Damestani
Poster
2021 ASCO Annual Meeting
A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.
First Author: Yazmin Odia
Poster
2022 ASCO Annual Meeting
Population-based retrospective analysis of response assessment criteria in patients with glioblastoma.
First Author: Parandoush Abbasian
Poster
2015 ASCO Annual Meeting
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
First Author: Ulrik Niels Lassen